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INTRODUCTION
Thyroxine is one of counter-regulatory hormone in glucose
homeostasis. Therefore, metabolic control in diabetes is nega-
tively affected by thyrotoxicosis. Typically, hyperglycemic hy-
perosmolar state (HHS) occurs in elderly individuals with type
2 diabetes mellitus (DM) accompanying with a several week
history of polyuria, weight loss, diminished oral intake and
decreased mentality in severe cases. HHS is often precipitat-
ed by a serious, concurrent illness such as myocardial infarc-
tion or systemic infections (1).
Although there have been several case reports describing
that diabetic ketoacidosis is associated with thyrotoxicosis in
type 2 diabetics (2-4), only one case of HHS associated with
Graves’ hyperthyroidism developed in type 2 diabetics has
been reported in the non-English literature until now (5). We
present the case of a young woman with type 2 DM and hy-
perthyroid Graves’ disease developing to HHS.
CASE REPORT  
A 23-yr-old woman with type 2 DM and Graves’ disease
has revisited to the Department of Emergency of Gyeongsang
National University Hospital due to nausea, generalized weak-
ness, polyuria and weight loss of 5 kg for 7 days in October
2003 since she was discharged from our hospital three weeks
before. She was previously diagnosed as type 2 DM in 1996,
and recently started insulin treatment to improve glycemic
control due to persistently elevated HbA1c irrespective of oral
administration of hypoglycemic agents. Three years before,
she had taken propylthiouracil for hyperthyroid Graves’ dis-
ease for 2 yr. In May 2003, she was diagnosed as relapse of hy-
perthyroidism at a local clinic and referred to our hospital
for management of thyrotoxicosis refractory to usual dosage
of propylthiouracil, 300 mg/day and proliferative diabetic re-
tinopathy and nephropathy. She had 7.9 mM/L fasting blood
glucose, 1.07 nM/L C-peptide (reference range [RR], 0.1-
0.83), 222 mM/L fructosamine (RR, 205-285), 8.3% HbA1c
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A Case of Hyperglycemic Hyperosmolar State Associated with Graves'
Hyperthyroidism
: A Case Report
Hyperglycemic hyperosmolar state (HHS) is an acute complication mostly occurring
in elderly type 2 diabetes mellitus (DM). Thyrotoxicosis causes dramatic increase
of glycogen degradation and/or gluconeogenesis and enhances breakdown of triglyc-
erides. Thus, in general, it augments glucose intolerance in diabetic patients. A 23-yr-
old female patient with Graves’ disease and type 2 DM, complying with methimazole
and insulin injection, had symptoms of nausea, polyuria and generalized weakness.
Her serum glucose and osmolarity were 32.7 mM/L, and 321 mosm/kg, respectively.
Thyroid function tests revealed that she had more aggravated hyperthyroid status;
0.01 mU/L TSH  and 2.78 pM/L free T3 (reference range, 0.17-4.05, 0.31-0.62, res-
pectively) than when she was discharged two weeks before (0.12 mU/L TSH and
1.41 pM/L free T3). Being diagnosed as HHS and refractory Graves’ hyperthyroidism,
she was treated successfully with intravenous fluids, insulin and high doses of methi-
mazole (90 mg daily). Here, we described the case of a woman with Graves’ disease
and type 2 DM developing to HHS.
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(RR, 4.5-5.6) and 0.01 mU/L TSH and 2.02 pM/L free T3
on thryoid function tests. At that time, Her weight was 54
kg and height was 147 cm (body mass index, 25.0 kg/m
2).
Her thyroid had the volume of about 40 g and it looked dif-
fusely enlarged and rubbery consistency on palpation. The
technetium-99m (Tc-99m) thyroid scan revealed marginally
increased and somewhat irregular uptake (3.8%). As from
hospitalization, the patient had oral administration of rela-
tively high dose of methimazole (60 mg daily), propranolol
(160 mg daily) and 12 drops of Lugol’s solution (three times
a day) for 14 days, and consecutively lithium carbonate (900
mg daily) for 14 days because of persisting tachycardia (>110/
min), dyspnea on exertion and still high concentration of free
T3 (4.44 pM/L). She was discharged with receiving methima-
zole (60 mg daily) and beta-blocker (Fig. 1).
She had no family history of thyroid disease, but both par-
ents have been suffering from type 2 DM. She denied inges-
tion of any drugs including alcohol or excessive consumption
of fizzy drinks these days. She also has been adhering to admi-
nistration of antithyroid drug, beta-blocker and insulin (0.5
units/kg/day) since being discharged. On physical examina-
tion, the patient had 143/89 mmHg blood pressure, 36.8℃
body temperature, 22/min respiration rate, and 121/min pulse
rate. She looked acutely ill, and had slightly tremulous, warm
hands, and decreased skin turgor and dried tongue. She was
48 kg weight and body mass index 22.2 kg/m
2. Exophthal-
mos was not present. The abdomen was soft and flat, and liver
and spleen were not palpable.
On admission, her laboratory findings were as follows; he-
moglobin 12.3 g/dL, WBC 8.65×10
9/L (segmented neutro-
phil 58%, lymphocyte 29%), platelet 398×10
9/L, total pro-
tein 65 g/L, albumin 32 g/L, ALP 3.47 ukat/L, AST 0.42 ukat/
L, ALT 0.6 ukat/L, BUN 9.2 mM/L and creatinine 88.7 M/L.
Levels of blood glucose (32.7 mM/L) and fructosamine (396
mM/L) were elevated. Her serum electrolytes and blood gas
parameters were as follows: sodium 144.1 mM/L, potassium
5.4 mM/L, chloride 102 mM/L, calcium 2.5 mM/L, phospho-
rus 1.0 mM/L, pH 7.32, pCO2 35 mmHg, pO2 98 mmHg,
and bicarbonate 16 mM/L. The fasting serum C-peptide was
0.44 nM/L. Serum anion gap was 20.9 and osmolarity was cal-
culated as 321 mosm/kg. Amylase and lipase levels were nor-
mal and anti-GAD antibody was negative. Thyroid function
tests revealed that the patient had more aggravated hyperthy-
roid state; 0.01 mU/L TSH, 2.78 pM/L free T3 and 45.38 pM/
L free T4 (RR, 11.41-23.08) than when she was hospitalized
two weeks before (0.12 mU/L TSH, 1.41 pM/L free T3 and
30.26 pM/L free T4). TSH-receptor antibody level was 26.3
IU/L (RR, <1) and antimicrosomal antibody was 29.3 U/mL
(RR, <60). The Tc-99m scan showed still enlarged thyroid
with more increased uptake 6.5% than previous uptake scan
(3.8%) performed taking propylthiouracil two months before.
Based on above results, the patient was diagnosed as HHS
accompanying mild ketosis on type 2 DM and aggravated
Graves’ hyperthyroidism. We treated her with intravenous
insulin injection and large volume of intravenous fluid admin-
istration. And also, she took high dose of methimazole (90 mg
daily, six times a day) and beta-blockers. On the second day,
nausea and generalized weakness have been improved. 
At two months after acute presentation, we measured levels
of C-peptide after 75 g glucose loading; 0 min (0.12 nM/L), 30
min (0.74 nM/L), 60 min (1.02 nM/L), 90 min (1.49 nM/L)
and 120 min (1.32 nML). Throughout follow-ups for 2 mon-
ths, she took insulin (0.9 units/kg/day), metformin (1,500
mg daily) and methimazole (45 mg daily). The mean fasting
capillary blood glucose level on self monitoring was rather
elevated than the target, but free T3 level became normalized
(Fig. 1).
DISCUSSION
Thyrotoxicosis is accompanied by multiple metabolic abnor-
malities, with increased energy expenditure and excessive mobi-
lization and utilization of metabolic substrates (6-8). Thyroid
hormones enhance hepatic glucose output by increasing glu-
cose metabolism such as gluconeogenesis and glycogenolysis
(9-11). So, appropriate management in diabetic patients with
hyperthyroidism is essential to control serum glucose level. In
addition, excess of thyroid hormone triggers the breakdown
of triglycerides stored in adipose tissue by enhancing lipid oxi-
dation, resulting in increase of concentration and turnover of
nonesterified fatty acids (9). Furthermore, hyperthyroidism
augments renal clearance of insulin (13) and predisposes pati-
ents with thyrotoxicosis to lead to severe hyperglycemia and
ketosis prone state. Therefore, these patients need more insulin
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Fig. 1. The clinical course and laboratory data of this patient.
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6.5% 3.8%administration. 
The patient in this case shows 32.7 mM/L serum glucose,
321 mosm/kg osmolarity, arterial blood pH 7.32, and weak
positive serum ketone on admission, suggesting that she has
HHS and mild ketosis. She was also in more aggravated thy-
rotoxic state on admission than when she was hospitalized.
Taking consideration of her good compliance to medication,
thyrotoxicosis refractory to treatments with high dose of me-
thimazole, and absence of any remarkable precipitating factors
such as severe stressful conditions, systemic infection, major
trauma, or myocardial infarction, and diseases or states elevated
counter-regulatory hormones, we concluded that uncontrolled
thyrotoxicosis might be a sole cause of her HHS development.
Although we can not give a clear explanation for the mecha-
nism why her Graves’ hyperthyroidism aggravated and be-
came resistant to high dose of antithyroid drug, we, here, sug-
gest several possible mechanisms. First, drugs administered
for thyrotoxicosis during first hospitalization might facilitate
the resistance of her thyroid tissue to methimazole. For exam-
ple, Lugol’s solution are known to induce thyrotoxicosis by
overriding the Wolff-Chaikoff effect in patients with nodu-
lar goiter (14). However, taking into account that Tc-99m
scan showed much higher uptake on HHS development com-
pared to first hospitalization (Fig. 1), this possibility looks
very low. It has been reported that thyrotoxicosis also occurs
in patients receiving long-term lithium carbonate for manic-
depressive illness by immunogenetic mechanisms in preva-
lence of 0.7% (15). The possibility, though, is also not much
regarding short duration of lithium exposure and promptness
of onset of more serious thyrotoxicosis, we could not rule out
that lithium carbonate might aggravate thyrotoxicosis by
intensifying underlying autoimmune mechanisms. Another
possibility is association of adrenergic receptor activation. For
example, stress like HHS or ketosis induces activation of sym-
pathetic nerves innervating the thyroid gland, and secretion
of catecholamines which, in turn, might stimulate the syn-
thesis of thyroid hormone (16). The elevated thyroid hormones
then cause increase of the density of beta-adrenergic receptors,
thereby enhances the effect of catecholamines. Lastly, though
she stated that she had been in compliance with administra-
tion of antithyroid drug, we can not entirely rule out the pos-
sibility of irregular adherence.
In conclusion, HHS, a major acute complication of type 2
DM, can lead to serious consequences in patient with Graves’
hyperthyroidism if not managed promptly and effectively. Al-
though HHS is rarely associated with Graves’ hyperthyroidi-
sm, here we confirm this unusual relation between HHS and
thyrotoxicosis in a type 2 diabetic woman who undergone
treatment with high dose of methimazole, Lugol’s solution and
lithium carbonate for refractory hyperthyroid Graves’ disease.
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